Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. - Wikidata - wikimedia - TriplyDB

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

http://www.wikidata.org/entity/Q43467235

about

Schizophrenia The myth of schizophrenia as a progressive brain disease Information and communication technology based prompting for treatment compliance for people with serious mental illness Maintenance treatment with antipsychotic drugs for schizophrenia Compliance therapy for schizophrenia Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia Pharmacologic treatment of schizophrenia Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns Schizophrenia relapse, patient considerations, and potential role of lurasidone Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review Medication adherence in schizophrenia Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review Meta-Analysis of Anti-Toxoplasma gondii IgM Antibodies in Acute Psychosis Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.Neuropsychologic functioning and structural MRI of the brain in patients with schizophrenia.The MATISSE study: a randomised trial of group art therapy for people with schizophrenia World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.What is the best approach to treating schizophrenia in developing countries?Appraising evidence for intervention effectiveness in early psychosis: conceptual framework and review of evaluation approaches.One-Year Follow-Up of Patients with a Diagnosis of First Episode Psychosis.Connectivity to computers and the Internet among patients with schizophrenia spectrum disorders: a cross-sectional study.Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder.Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders.Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system.Increasing medication adherence and income assistance access for first-episode psychosis patients.Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.Early detection and intervention in first-episode schizophrenia: a critical review.Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.A Longitudinal Examination of the Moderating Effects of Symptoms on the Relationship between Functional Competence and Real World Functional Performance in Schizophrenia.Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments.Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.Adherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian population World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.

P2860

Q22242092-AD787F19-180E-4635-A5FB-8AF98DF86BCA Q24067152-66F4E562-1F2F-4A0A-9127-99B7D7CB4CA1 Q24193953-6EADDF47-7B71-49C0-94E8-77D1DF302F86 Q24197902-F4BB4C49-71A3-4CB6-977B-A08A2CC9AA3A Q24244947-9C60ADDD-0EB2-4587-BF26-9EEAEDD50C1C Q24597701-F0574F8B-BF68-4656-BCE4-3BFC387B2D4D Q24604457-F8DC3952-19E5-49A1-A352-3229C91CD29D Q24802626-83B2E83D-0C4A-4D94-A68B-5A113C9171CD Q26738850-E09707E1-3B15-4D16-BED3-7AB5AAE68E1A Q26770497-A81B984F-FB39-4F36-921D-C732EC7A0611 Q26823655-44F65EB7-1584-4CF6-A8FB-41AD3203CE73 Q26863435-54B985B1-01A0-467A-8265-427C38354361 Q28079821-E3ABD952-F205-49C5-87E1-47373F21416D Q28648499-A9FE27E6-DD8A-4280-AB6E-AFBEFEB918B5 Q30428213-F0BE97BB-4F9A-41B3-ACBD-3A3AF537736E Q30988161-83D19F20-47F3-423B-A92C-BED6C7D809F0 Q30988171-9E387432-1C9B-4909-B4ED-F0555BAADE84 Q33223628-40937B4F-C542-4ACA-8A38-93D55E71FA72 Q33235110-F43A5EA3-8D85-4CBA-8FED-8C69F3A5F16B Q33288244-BF670E2C-3F25-4381-9B37-37F83A942656 Q33533853-8883AC5D-DBA5-4582-BCA4-989B40B0ABBF Q33594616-12C84FD6-C1C1-438B-B2CA-F0176E049BE2 Q33631296-587A0D41-97E0-4A97-9CEE-4AD12172C695 Q33633758-199B7B96-6BD7-4275-995E-520A5361B8CA Q33662622-E9530CEE-207B-480A-B11C-41E79441437F Q33680103-CBAC9A1C-C544-46CA-98E8-CF1E367D5245 Q33713167-3C44CD86-B989-486A-8901-2386FDE60731 Q33773223-1804789C-645B-4E44-9DAB-4F3411C3A85E Q33797431-6C925F86-B12F-4F9F-9A2C-91570A89B8E4 Q33814003-F0E3A6B7-2E63-415F-B888-3F18FEDA6C2F Q33857710-35B1E768-B098-47A6-90AF-F82B79830371 Q33948803-88D02371-18D8-444C-B87B-F6D119489F00 Q34075734-7C4708EF-8CE2-407A-8851-1970388FA5CA Q34245341-14CA5AEC-08A3-48CC-92EC-5F2EB11BF141 Q34266206-46D16A7D-1353-4958-A853-EA215ECD2E51 Q34293899-F60CD2D2-F1F2-40AC-9862-D8599EACE4A5 Q34308009-A78FF255-E659-4BB8-89F5-A2E0A79AA7AC Q34315836-1589E7A4-29F8-4F6D-9DA7-EEAFAB3CF1AF Q34318836-17967DBD-D783-4C2F-BECB-0890F071AAD0 Q34386214-D22CC998-39E6-4448-A803-474713D7DC27

P2860

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

http://www.wikidata.org/entity/Q43467235

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh-hant

name

Predictors of relapse followin ...... a or schizoaffective disorder.

@en

Predictors of relapse followin ...... a or schizoaffective disorder.

@nl

type

label

Predictors of relapse followin ...... a or schizoaffective disorder.

@en

Predictors of relapse followin ...... a or schizoaffective disorder.

@nl

prefLabel

Predictors of relapse followin ...... a or schizoaffective disorder.

@en

Predictors of relapse followin ...... a or schizoaffective disorder.

@nl

P1433

Q43467235-5EA5A595-F0C9-406D-A791-A41D66C0B9B2

P1476

Q43467235-AA96BCD2-A27A-4967-85F1-D23113A5F289

P2093

Q43467235-14B59F25-E045-45DB-BE20-2B268826F213

Q43467235-2664AA58-5A2C-4639-BAD7-39FFD7746876

Q43467235-3910657C-6B8C-449B-A31E-023E30D0356F

Q43467235-3E02643B-BAC3-4DB4-A7F6-7E822CD151A0

Q43467235-5ADEF91D-26FF-40AA-980A-6DAC01603F89

Q43467235-61E221EE-7597-441F-BF9C-93A1BD715D98

Q43467235-719F00E2-3C07-48D6-A05B-7C434DD49882

Q43467235-7994174F-5D3B-4254-BC77-5AA025CB1406

Q43467235-9E040FB6-6EAC-4243-83D9-8D73A4AD458D

Q43467235-B79F48D9-AA74-44F1-B42D-77A00C0C6CCC

P304

Q43467235-C286AB09-6D4E-4B0F-ABF6-91042898AD58

P31

Q43467235-86D1BA98-B5CD-4CAA-B04A-F6300B2AACAA

P356

Q43467235-5D795954-0352-4561-A619-13F7A3613D61

P407

Q43467235-8014D910-E4FC-4463-8D6E-173B63F0016C

P433

Q43467235-DFD59A46-05BE-40AF-AABA-87824E7E4E6E

P478

Q43467235-B4183A25-B0F2-41EF-8D7A-A72C3E462247

P577

Q43467235-9FDD8460-3B38-4AB2-87F4-8383FC4C0391

P5875

Q43467235-E18C224A-15F4-4C90-A4AB-7771941F285B

P698

Q43467235-F23A3B0B-2B1C-4B3A-8649-D739CC0D4CD3

P921

Q43467235-E84B3E98-F370-412B-87A8-88E08F8B8711

P356

ARCHPSYC.56.3.241

P1433

JAMA Psychiatry

P1476

Predictors of relapse followin ...... a or schizoaffective disorder.

@en

P2093

Alvir JM

http://www.w3.org/2001/XMLSchema#string

Bilder R

http://www.w3.org/2001/XMLSchema#string

Chakos M

http://www.w3.org/2001/XMLSchema#string

Geisler S

http://www.w3.org/2001/XMLSchema#string

Goldman R

http://www.w3.org/2001/XMLSchema#string

Koreen A

http://www.w3.org/2001/XMLSchema#string

Lieberman JA

http://www.w3.org/2001/XMLSchema#string

Mayerhoff D

http://www.w3.org/2001/XMLSchema#string

Robinson D

http://www.w3.org/2001/XMLSchema#string

Sheitman B

http://www.w3.org/2001/XMLSchema#string

P304

241-247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHPSYC.56.3.241

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

1999-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13211466

http://www.w3.org/2001/XMLSchema#string

P698

10078501

http://www.w3.org/2001/XMLSchema#string

P921